Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

NCT05585996 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Relapsed and Refractory B-cell Lymphoma

Interventions

BIOLOGICAL: CD19 CAR-T and CD19 CAR-DC

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University